

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|                                       |   |                            |
|---------------------------------------|---|----------------------------|
| In re Patent Application of           | ) |                            |
|                                       | ) |                            |
| LINSELL et al.                        | ) | Confirmation No.: 3562     |
|                                       | ) |                            |
| Application No.: 10/627,555           | ) | Group Art Unit: 1621       |
|                                       | ) |                            |
| Filed: July 25, 2003                  | ) | Examiner: Shailendra Kumar |
|                                       | ) |                            |
| For: CRYSTALLINE $\beta_2$ ADRENERGIC | ) |                            |
| RECEPTOR AGONIST                      | ) |                            |
|                                       | ) |                            |
|                                       | ) |                            |

**STATEMENT DELETION OF INVENTOR(S)**  
**PURSUANT TO 37 CFR § 1.48(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request that the inventorship of the above-identified patent application be amended to delete the names of those persons who are not inventors of the presently claimed subject matter.

Specifically, Applicants request that the inventorship be amended to delete Martin S. Linsell, John R. Jacobsen and Weijiang Zhang. These persons were correctly named as inventors of the claimed invention as originally filed, but they are not inventors of the invention now being claimed in the present application.

The remaining named inventors, Davar Khossravi and Mehdi Paborji are correctly named as inventors of the claimed invention.

The Commissioner is hereby authorized to charge the processing fee set forth in §1.17(i) for this amendment to Deposit Account No. 50-0344. Additionally, the

Commissioner is hereby authorized to charge any additional fees required by this paper,  
or to credit any overpayment, to Deposit Account No. 50-0344.

Respectfully submitted,

Date: April 18, 2008

By: /Roberta P. Saxon/  
Roberta P. Saxon  
Reg. No. 43,087

THERAVANCE, INC.  
901 Gateway Boulevard  
South San Francisco, CA 94080  
Tel: (650) 808-6000  
Fax: (650) 808-6078